Literature DB >> 7785000

rhDNase in cystic fibrosis.

S P Range, A J Knox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7785000      PMCID： PMC474258          DOI： 10.1136/thx.50.4.321

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  13 in total

1.  Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections.

Authors:  R SPIER; E WITEBSKY; J R PAINE
Journal:  JAMA       Date:  1961-12-02       Impact factor: 56.272

2.  A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

Authors:  R C Hubbard; N G McElvaney; P Birrer; S Shak; W W Robinson; C Jolley; M Wu; M S Chernick; R G Crystal
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

3.  Aerosols of pancreatic dornase in bronchopulmonary disease.

Authors:  A SALOMON; J A HERCHFUS; M S SEGAL
Journal:  Ann Allergy       Date:  1954 Jan-Feb

4.  Deoxyribonuclease in the treatment of purulent bronchitis.

Authors:  P C ELMES; J C WHITE
Journal:  Thorax       Date:  1953-12       Impact factor: 9.139

5.  Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions.

Authors:  J L Potter; L W Matthews; S Spector; J Lemm
Journal:  Pediatrics       Date:  1965-11       Impact factor: 7.124

6.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

7.  Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

Authors:  C Ranasinha; B Assoufi; S Shak; D Christiansen; H Fuchs; D Empey; D Geddes; M Hodson
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

8.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

9.  Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

Authors:  B W Ramsey; S J Astley; M L Aitken; W Burke; A A Colin; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; D V Schidlow
Journal:  Am Rev Respir Dis       Date:  1993-07

10.  Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

Authors:  P L Shah; S F Scott; H J Fuchs; D M Geddes; M E Hodson
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139
View more
  3 in total

1.  Recombinant human DNase (rhDNase) in cystic fibrosis: is it cost effective?

Authors:  S P Conway
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 2.  The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

Authors:  M S Zach
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis.

Authors:  C E Milla
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.